Back to search

University of Ioannina

Αποτελεσματικότητα της θεραπείας με υψηλή δόση ροσουβαστατίνης σε σύγκριση με χαμηλή δόση ροσουβαστατίνης σε συνδυασμό με φαινοφιμπράτη ή με χαμηλή δόση ροσουβαστατίνης σε συνδυασμό με Ω-3 λιπαρά σε ασθενείς με μεικτή υπερλιπιδαιμία

Abstract

dc:description

Background: Mixed or combined hyperlipidemia is a common metabolic disorder characterized by elevated concentrations of both cholesterol and triglycerides (TG). Metabolic syndrome (MetS) is characterized by raised TG together with low high density lipoprotein cholesterol (HDL-C) levels and a predominance of small dense low density lipoproteins (sdLDL). Mixed hyperlipidemia, oxidative stress and inflammation are related to a high risk for cardiovascular events.Objective: The aim of the study was to compare the efficacy of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega-3 fatty acids on anthropometric variables, lipid profile, inflammatory markers and carbohydrate metabolism parameters, as well as on LDL and HDL phenotype and activities of atherosclerosis-related enzymes, in patients with mixed hyperlipidemia. Methods: Ninety patients with mixed hyperlipidaemia (LDL-C > 160 and TG > 200 mg/dl) participated in the study. Patients were randomly allocated to receive for 3 months rosuvastatin 40 mg (n = 30, group R), rosuvastatin 10 mg plus fenofibrate 200 mg (n = 30, group RF) or rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (n = 30, group RΩ).Results: Three patients dropped out, whereas 87 patients completed the study. After 3 months of treatment 28% of patients in the R group, 54.2% in the RF group and 29.2% in the RΩ group no longer met the MetS diagnostic criteria (p < 0.01 vs. baseline in all treatment groups). No alterations in body weight, BMI, waist circumference and blood pressure were observed after 3 motnhs of treatment. Non-HDL-C levels were reduced in all groups: in R group by 54%, in RF group by 42% and in RΩ group by 42%. Significant reductions in TCHOL, LDL-C and TG levels were observed in all groups. The reductions in total and LDL-C were greatest in the R group, while a more pronounced reduction of TGs in the RF group compared with that in the R and the RΩ group was observed. HDL-C levels were significantly increased only in the RF group. The mean LDL size was significantly increased in all groups. This change was more prominent with RF than with other treatments in parallel with its greater hypotriglyceridemic capacity (p<0.05 compared with R and Rω). A decrease in insulin resistance with RF was also important. Only RF significantly raised HDL-C levels (by 7.7%, p<0.05) by increasing the cholesterol of small HDL particles. However, the cholesterol of larger HDL subclasses was significantly increased by R and RΩ. In all treatment groups a significant reduction in total plasma LpPLA2 activity was observed (by 41, 38 and 30% for groups R, RF and RΩ, respectively). This decrease was greater in the R and RF groups compared with the RΩ combination (p < 0.05). HDL-LpPLA2 activity was increased more in the RF group (+43%) compared with the R and RΩ groups (+ 18% and + 35%, respectively; p < 0.05 for both comparisons). A 53% reduction of hsCRP levels was observed in the R group, while in the RF and RΩ groups smaller reductions were notified by 28 and 23%, respectively (p < 0.05 and p < 0.01 for the comparisons of group R with groups RF and RW, respectively). No significant changes were observed in PON1 activities in all treatment groups.Conclusion: High doses of rosuvastatin and small doses of rosuvastatin plus either fenofibrate or n-3 fatty acids exhibit favorable effects on both LDL-C and non-HDL-C levels. However, rosuvastatin monotherapy more potently reduces these parameters. Moreover, rosuvastatin monotherapy has a more potent effect on LpPLA2 activity and hsCRP compared with rosuvastatin plus fenofibrate or rosuvastatin plus ω-3 fatty acids in patients with mixed hyperlipidemia. The combination of rosuvastatin plus fenofibrate leads to a greater decrease in triglyceride levels and a greater increase in HDL-C levels compared with the other two treatments. In addition, all regimens increase mean LDL size. However, RF is the most effective in increasing mean LDL size. A differential effect of treatments was noted on the HDL subfraction profile. All in all, high doses of rosuvastatin may represent the treatment of choice in individuals with mixed dyslipidemia.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Angouridis, Aris-Dimitrios
  • Αγγουρίδης, Άρης-Δημήτριος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44441

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Angouridis, Aris-Dimitrios; Αγγουρίδης, Άρης-Δημήτριος. Αποτελεσματικότητα της θεραπείας με υψηλή δόση ροσουβαστατίνης σε σύγκριση με χαμηλή δόση ροσουβαστατίνης σε συνδυασμό με φαινοφιμπράτη ή με χαμηλή δόση ροσουβαστατίνης σε συνδυασμό με Ω-3 λιπαρά σε ασθενείς με μεικτή υπερλιπιδαιμία. University of Ioannina, 2017. http://hdl.handle.net/10442/hedi/44441